论文部分内容阅读
经协商,中国科学院上海药物所、上海药物研究所-阿斯利康药物安全性评价联盟、中国药学会和Astra Zeneca将联合举办系列新药创制高层学术研讨会。首届新药创制高层学术研讨会将于2014年12月2日至3日在上海市召开,会议主题:以转化毒理学为核心的新药成药性研发的风险控制、策略和挑战。现将有关事宜通知如下。1会议内容药物安全性问题是新药研发过程终止或撤市最常见的原因,“Fail earlier,Fail cheaper”这是整个制药行业所面临的巨大
After consultation, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Institute of Materia Medica - AstraZeneca Drug Safety Evaluation Alliance, Chinese Pharmaceutical Association and Astra Zeneca will jointly hold a series of high-level academic seminar on the creation of new drugs. The first high-level symposium on the creation of new drugs will be held in Shanghai from December 2 to December 3, 2014. The theme of the conference is: Risk Control, Strategy and Challenges for the Research and Development of New Drugs Based on Translational Toxicology. The relevant matters are hereby notified as follows. 1 Conference Content The drug safety issue is the most common reason for the termination or withdrawal of a drug development process. “Fail earlier, Fail cheaper” This is a huge challenge for the entire pharmaceutical industry